KV Pharma axes CEO

A month after laying off 42 percent of its workforce, KV Pharmaceutical has elected new board members who promptly turned around and ousted the CEO, David Van Vliet. The board initiated a search for a new CEO, who will have to complete a turnaround triggered by an FDA inspection and product recalls, and get the company's products back on the market. Van Vliet is entitled to a $1 million severance package, about twice his annual salary. KV release

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.